<DOC>
	<DOCNO>NCT01752686</DOCNO>
	<brief_summary>This study design investigate efficacy carboplatin , post-operative adjuvant chemotherapy triple negative breast cancer patient pathologic residual cancer preoperative chemotherapy .</brief_summary>
	<brief_title>A Phase III Trial Carboplatin Adjuvant Chemotherapy Triple Negative Breast Cancer</brief_title>
	<detailed_description>In Neo-adjuvant period Four cycle 60 mg/m2 doxorubicin 600 mg/m2 cyclophosphamide therapy 3-week interval follow four cycle 100 mg/m2 docetaxel 3-week interval . In POST Neo-adjuvant period Randomization : At time post neo-adjuvant period , patient assign treatment group 1:1 ratio i.e . carboplatin AUC 6 group vs. observation group . Six cycle carboplatin ( AUC=6 ) first day every 21 day .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Clinical diagnosis breast cancer 1 . Female patient 2 . Histologically confirm invasive breast cancer 1 . Primary tumor great 2cm diameter , measure mammography sonography 2 . Any N 3 . ER ( estrogen receptor ) / PR ( progesterone receptor ) / HER2 ( negative/ negative/ negative ) ( ER &lt; 1 % , PR &lt; 1 % , IHC 0 , 1+ FISH case IHC ( immunohistochemistry ) 2+ ) 4 . No evidence metastasis ( M0 ) 5 . No prior hormonal , chemotherapy radiotherapy allow . 6 . No breast operation biopsy make diagnosis allow . 7 . Age : 20years old , pregnant pre , postmenopausal woman good performance status ( ECOG 01 ) 8 . Adequate hematopoietic function : Absolute granulocyte count 1500/mm3 , platelet 100,000/mm3 , Hemoglobin 10 g/mm3 9 . Adequate renal function : Serum creatinine 1.5 mg/dl 10 . Adequate hepatic function : total bilirubin : 1.5 mg/dl , AST ( aspartate aminotransferase ) /ALT ( alanine transaminase ) : 2 time normal , Alkaline phosphatase:2 time normal 11 . Written inform consent 12 . Normal mental function understand sign consent 13 . Cardiac function : normal nonspecific EKG take within 1 mo enrollment . 14 . LVEF ( leave ventricular ejection fraction ) 50 % MUGA ( multiple gate acquisition scan ) Echocardiogram take within 1 mo enrollment 1 . Patients receive hormonal , chemotherapy radiotherapy breast cancer 2 . Patients underwent surgery breast cancer 3 . Patients history uncompensated congestive heart failure 4 . Patients inflammatory breast cancer ( T4d ) 5 . Patients without primary tumor ( T0 ) 6 . Patients history cancer situ uterine cervix cancer nonmelanotic skin cancer 7 . Known hypersensitivity study drug</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Triple negative breast cancer</keyword>
	<keyword>adjuvant chemotherapy</keyword>
</DOC>